A drug from the Dutch biotech Merus designed to disrupt a rare genetic alteration is showing early but promising anti-tumor responses in patients with advanced pancreatic cancer — a disease with few effective treatment options available.
When treated with infusions of the Merus drug, called zenocutuzumab, four of 10 patients with pancreatic cancer showed partial responses, for a confirmed overall response rate of 40%. Another three patients had minor tumor responses.
The new zenocutuzumab data were disclosed Wednesday night in a research abstract for the annual meeting of the American Society of Clinical Oncology, which takes place next month. The abstract is only an early snapshot of the zenocutuzumab results assessed last January, with more fulsome data with longer follow-up coming at the ASCO meeting.
About the Author Reprints
